Partikula Announces $5 Million Series A Funding to Develop Novel First-In-Class Mitochondrial Targeted Therapeutics

Davie, Florida – February 2, 2015 – Partikula, LLC (“Partikula”), a preclinical stage biopharmaceutical company, announced today its closing of a Series A financing. 2M Companies led the $5 million round. Partikula will use the proceeds from this financing to support the development of its portfolio of novel mitochondrial-targeting agents, initially focusing on inhibitors of cancer metabolism and survival. Partikula was formed in 2013 by seasoned life science entrepreneur and CEO David Kolb to capitalize on novel chemistries capable of delivering therapeutic agents directly to the mitochondria. “Utilizing our platform chemistries we are able to access a wealth of well studied but difficult to reach targets that control a variety of important cellular functions”, commented Mr. Kolb. Dr. Marc Lippman, Deputy Director of the Sylvester Cancer Center at the University of Miami and the company’s Chief Medical Officer, added, “with its mitochondrial targeting platform, Partikula can now access hard-to-reach targets that control a variety of important cellular mechanisms and pathways including metabolism, apoptosis, fission/fusion, physiological sensing and cell cycle maintenance with applicability across many therapeutic areas beginning with oncology but reaching out across neurology, cardiology, metabolic disease and rare orphan diseases.” Partikula is initially applying its platform technology in the area of oncology. The company has developed a family of metabolic inhibitors including therapeutics that target pyruvate dehydrogenase kinase (PDK) and hexokinase (HK), both essential elements of cellular metabolism pathways that are significantly augmented in many forms of cancer. “By inhibiting cancer metabolism at its core location we hope to have a potent and specific effect against cancer cells while avoiding resistance mechanisms and crosstalk upstream of the mitochondria,”...